Mode
Text Size
Log in / Sign up
N/A N=357 Screening

Hemangioma Associated With High Rates of Morbidity

Hemangioma

Enrolled (actual)
357
Serious AEs
0.0%
Results posted
Jul 2011
Primary outcome: Primary: MRI/MRA of Head/Neck/Chest. — 357 participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
MRI (Device); MRI of head and neck (Device); Dermatological Examination (Other); Cardiac examination (Other); Abdominal ultrasound (Device)
Age
Pediatric, Adult
Sex
All
Sponsor
Medical College of Wisconsin
Primary completion
Nov 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
MRI/MRA of Head/Neck/Chest.
357
PRIMARY
Clinical Diagnosis of PHACE Syndrome
33
PRIMARY
Spinal Abnormalities
21
PRIMARY
Cerebrovascular and Structural Brain Abnormalities
31
PRIMARY
Cardiac Abnormalities Detected Via Clinical Examination
22
PRIMARY
Frequency of Hepatic Hemangiomas Detected Via Abdominal Ultrasound
24

Summary

We are conducting a study on the possible presence of PHACES in children with large facial hemangiomas and lumbosacral hemangiomas of infancy (hemangioma in the lower back) . With this study we hope to better understand the risk of this syndrome and to develop guidelines for its evaluation and management.

Eligibility Criteria

Segmental Facial Hemangioma

Inclusion criteria

  • Infants less than 1 year of age
  • Hemangiomas of the head /facial area measuring 22cm2 or greater.

Exclusion criteria

  • Children greater than 1 year of age.
  • Children with segmental hemangiomas present in locations other than the head.
  • Children presenting with localized (focal) or indeterminate hemangiomas in any location.
  • Children with other vascular tumors (such as tufted angioma, Kaposiform hemangioendothelioma, non-involuting congenital hemangioma or rapidly-involuting congenital hemangioma) or vascular malformations.

Lumbosacral Hemangioma

Inclusion criteria

  • Individuals less than 18 years of age.
  • Hemangioma, hemangioma precursor, or definitive residual hemangioma larger then 2.5 cm in diameter, overlying the midline lumbar spine or sacral spine in which any portion of the hemangioma is located over the midline.

Exclusion Criteria

  • Excluding perirectal hemangiomas that do not extend onto the sacral spine.
  • Excluding perineal hemangiomas that do extend to overlay the sacral spine.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00394888). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search